MEOBFOTCinactive

MESOBLAST LTD

Healthcare·Immunology·Phase 3·Melbourne, VIC, Australia
ImmunologyCardiovascular

MESOBLAST LTD (MEOBF): 2 pipeline candidates. Updated within the last hour.

6.6/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for MESOBLAST LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$2.0B

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (2 candidates)

DrugPhase
prochymal adult human mesenchymal stem cellsPhase 3
rexlemestrocel-lPhase 3
·CEO: Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Frequently asked questions

How many drug candidates are in MESOBLAST LTD's pipeline?

MESOBLAST LTD (MEOBF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is MESOBLAST LTD's lead drug candidate?

MESOBLAST LTD's most advanced tracked candidate is prochymal adult human mesenchymal stem cells (Phase 3) for Crohn's Disease.

What is MESOBLAST LTD's market capitalization?

MESOBLAST LTD's market capitalization is approximately $2.0B.

Who is the CEO of MESOBLAST LTD?

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) is the chief executive officer of MESOBLAST LTD (MEOBF).

Get the full picture on MESOBLAST LTD

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar